Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Feb 15:9:70.
doi: 10.3389/fonc.2019.00070. eCollection 2019.

Patterns of Bone Failure in Localized Prostate Cancer Previously Irradiated: The Preventive Role of External Radiotherapy on Pelvic Bone Metastases

Affiliations

Patterns of Bone Failure in Localized Prostate Cancer Previously Irradiated: The Preventive Role of External Radiotherapy on Pelvic Bone Metastases

Mathieu Grapin et al. Front Oncol. .

Abstract

Introduction: External beam radiation therapy (EBRT) can cure localized prostate cancer (PCa) by sterilizing cancer cells in the prostate gland and surrounding tissues at risk of microscopic dissemination. We hypothesized that pelvic EBRT for localized PCa might have an unexpected prophylactic impact on the occurrence of pelvic bone metastases. Material and Methods: We reviewed the data of 332 metastatic PCa patients. We examined associations between the number (≤5 vs. >5) and the location of bone metastases (in-field vs. out-of-field), which occurred at first relapse, and a previous history of EBRT for PCa (EBRT vs. No-EBRT). Results: One hundred and ten patients M0 at baseline were eligible. Fifty-six patients (51%) were in the No-EBRT group, and 54 patients (49%) in the EBRT group. The proportion of patients who developed >5 bone metastases in the bony pelvis was higher in the No-EBRT group vs. the EBRT group: 10 patients (18%) vs. 2 patients (4%), respectively (p = 0.02). By multivariate analysis EBRT was associated with a lesser occurrence of patients who had >5 bone metastases in the bony pelvis (OR = 0.17 [95%CI, 0.04-0.87], p = 0.03). Time to occurrence of bone metastases ≥5 years (OR = 0.10 [95%CI, 0.05-0.19], p < 0.01), prior curative prostate treatment (OR = 0.58 [95%CI, 0.36-0.91], p = 0.02), >5 bone metastases in bony pelvis (OR = 2.61 [95%CI, 1.28-5.31], p < 0.01), >5 bone metastases out of bony pelvis (OR = 1.73 [95%CI, 1.09-2.76], p = 0.02) were all predictive of overall survival. Conclusion: Previous pelvic EBRT for PCa is associated with a lower number of pelvic bone metastases, which is associated with better overall survival.

Keywords: metastasis; patterns of failure; prostate cancer; radiotherapy; surgery.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Pattern of occurence of bone metastases >5 in the external beam radiation therapy (EBRT) and No-EBRT-groups. Gray circles indicate the proportion of bone metastases > 5 inside and outside the pelvis. (A) Bone scan from a patient in the EBRT group who developed multimetastatic disease outside the pelvis. The pelvis is defined as the bone anatomy between the 2 dotted lines. The black arrow shows the limit of the prostate or prostate bed radiation (PPBR) field. There is a clear decrease of the bone uptake in-field. (B) Bone scan from a patient in the No-EBRT group. This man developed a multimetastatic disease including the pelvis.
Figure 2
Figure 2
Overall survival curves from initial diagnosis, among patients with localized prostate cancer according to: (A) Whether they received External Beam Radiation Therapy (EBRT group) or not (No-EBRT group). (B) Presence of ≤5 bone metastases compared to >5 bone metastases in the bony pelvis at first bone relapse.

Similar articles

References

    1. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA (1998) 280:969–74. - PubMed
    1. Rozet F, Hennequin C, Beauval JB, Beuzeboc P, Cormier L, Fromont G, et al. Recommandations en onco-urologie 2016-2018 du CCAFU: Cancer de la prostate. Prog En Urol. (2016) 27:S95–143. 10.1016/S1166-7087(16)30705-9 - DOI - PubMed
    1. Zumsteg ZS, Spratt DE, Pei I, Zhang Z, Yamada Y, Kollmeier M, et al. . A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy. Eur Urol. (2013) 64:895–902. 10.1016/j.eururo.2013.03.033 - DOI - PubMed
    1. Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff R-O, et al. . Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet Lond Engl. (2002) 360:103–6. 10.1016/S0140-6736(02)09408-4 - DOI - PubMed
    1. Mason MD, Parulekar WR, Sydes MR, Brundage M, Kirkbride P, Gospodarowicz M, et al. . Final report of the intergroup randomized study of combined androgen-deprivation therapy plus radiotherapy versus androgen-deprivation therapy alone in locally advanced prostate cancer. J Clin Oncol Off J Am Soc Clin Oncol. (2015) 33:2143–50. 10.1200/JCO.2014.57.7510 - DOI - PMC - PubMed

LinkOut - more resources